The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

(VRS): Verbal Rating Scales; (BP-EP): Breakthrough or intense Episodic Pain; (CI): Confidence Interval. CB participated in the design of the study, performed the statistical analysis and drafted ...

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...

Pain intensity during and after cycling was measured using a numerical pain rating scale. Results The NSCLBP (FP) subjects were significantly more flexed (P=.018) at the lower lumbar spine during ...

LONDON, Jan 7 (Reuters) - There is a 30%-40% chance that France will see further negative credit rating moves this year unless the government can finally find a way to rein in its spending ...

This study, comparing NRS and VRS psychometric properties in the assessment of pain exacerbations, reveals a significantly higher discriminatory capability of NRS in distinguishing between ...